Top

BMC Cancer

Published in:

Open Access 01-12-2021 | NSCLC | Research article

LncRNA WT1-AS downregulates lncRNA UCA1 to suppress non-small cell lung cancer and predicts poor survival

Authors: Yanhui Wan, Da Yao, Fuyuan Fang, Youyu Wang, Guodong Wu, Youhui Qian

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

LncRNA WT1-AS inhibits gastric cancer, while its role in other cancers is unknown. We investigated the role of WT1-AS in non-small cell lung cancer (NSCLC).

Methods

Sixty-six NSCLC patients (40 males and 26 females; 36 to 68 years old; mean age 52.7 ± 6.4 years old) were selected from the 178 NSCLC patients operated on for lung cancer between 2010 and 2013. RT-qPCR was used to analyze the expression of lncRNA. Overexpression experiments were performed to assess interactions between lncRNAs. CCK-8 assay was carried to evaluate the roles of WT1-AS and UCA1 in regulating cell proliferation. Cell invasion and migration assays were performed to assess the roles of WT1-AS and UCA1 in regulating cell invasion and migration. Western-blot was performed to illustrate the effect of WT1-AS and UCA1 in EMT.

Results

WT1-AS was downregulated in NSCLC and was correlated with poor survival. The expression of WT1-AS in NSCLC was not correlated with clinical stages. LncRNA UCA1 was upregulated in cancer tissues and inversely correlated with WT1-AS. Overexpression of UCA1 did not affect WT1-AS, while overexpression of WT1-AS led to inhibited expression of UCA1. Overexpression of UCA1 resulted in increased proliferation, EMT, migration and invasion of NSCLC cells, while overexpression of WT1-AS showed opposite effects. In addition, overexpression of UCA1 inhibited the role of overexpression of WT1-AS.

Conclusions

Therefore, overexpression of WT1-AS may inhibit the cell proliferation and EMT to decrease cell migration and invasion of NSCLC cells by downregulating UCA1.

Available only for authorised users

Boloker G, Wang C, Zhang J. Updated statistics of lung and bronchus cancer in United States (2018). J Thorac Dis. 2018;10(3):1158–61. https://doi.org/10.21037/jtd.2018.03.15.CrossRefPubMedPubMedCentral

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Cancer Netw. 2016;14(3):255–64.CrossRef

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.CrossRefPubMed

Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3(8):819–31. https://doi.org/10.1097/JTO.0b013e31818020eb.CrossRefPubMed

Gazdar AF, Zhou C. Lung cancer in never-smokers : a different disease. IASLC Thoracic Oncology. Philadelphia: Elsevie; 2018. p. 23–9.CrossRef

Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21. https://doi.org/10.1038/nrg3606.CrossRefPubMed

Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14(11):699–712. https://doi.org/10.1038/nrm3679.CrossRefPubMedPubMedCentral

Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–66. https://doi.org/10.1016/j.canlet.2013.06.013.CrossRefPubMed

Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703–19. https://doi.org/10.4161/rna.20481.CrossRefPubMedPubMedCentral

10.

Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol. 2013;45(8):1895–910. https://doi.org/10.1016/j.biocel.2013.05.030.CrossRefPubMed

11.

Du T, Zhang B, Zhang S, Jiang X, Zheng P, Li J, et al. Decreased expression of long non-coding RNA WT1-AS promotes cell proliferation and invasion in gastric cancer. Biochim Biophys Acta. 2016;1862(1):12–9. https://doi.org/10.1016/j.bbadis.2015.10.001.CrossRefPubMed

12.

Nie W, Ge HJ, Yang XQ, Sun X, Huang H, Tao X, et al. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett. 2016;371(1):99–106. https://doi.org/10.1016/j.canlet.2015.11.024.CrossRefPubMed

13.

Yang J, Lin J, Liu T, Chen T, Pan S, Huang W, et al. Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer. 2014;85(2):110–5. https://doi.org/10.1016/j.lungcan.2014.05.011.CrossRefPubMed

14.

Yang YR, Zang SZ, Zhong CL, Li YX, Zhao SS, Feng XJ. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. Int J Clin Exp Pathol. 2014;7(10):6929–35.PubMedPubMedCentral

15.

Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer. 2013;13:461. https://doi.org/10.1186/1471-2407-13-461.CrossRefPubMedPubMedCentral

16.

Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17. https://doi.org/10.1016/j.csbj.2014.11.005.CrossRefPubMed

17.

Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015;6(26):22513–25. https://doi.org/10.18632/oncotarget.4154.CrossRefPubMedPubMedCentral

18.

Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao T, et al. LncRNA-HOST2 regulates cell biological behaviors in epithelial ovarian cancer through a mechanism involving microRNA let-7b. Hum Mol Genet. 2015;24(3):841–52. https://doi.org/10.1093/hmg/ddu502.CrossRefPubMed

Title: LncRNA WT1-AS downregulates lncRNA UCA1 to suppress non-small cell lung cancer and predicts poor survival
Authors: Yanhui Wan
Da Yao
Fuyuan Fang
Youyu Wang
Guodong Wu
Youhui Qian
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: NSCLC
NSCLC
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-07767-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

High regional mortality due to malignant melanoma in Eastern Finland may be explained by the increase in aggressive melanoma types

Temporality of clinical factors associated with pancreatic cancer: a case-control study using linked electronic health records

The role of education on Cancer amenable mortality among non-Hispanic blacks & non-Hispanic whites in the United States (1989–2018)

Identification of TRPV4 as a novel target in invasiveness of colorectal cancer

The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines

Food and Drug Administration approvals in phase 3 Cancer clinical trials

Keynote webinar | Spotlight on antibody–drug conjugates in cancer